Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

Visit https://www.peervoice.com/DGN860 to view the entire programme with slides. After completing “Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer”, participants will be able to: Assess the clinical significance of clinical trial data evaluating the safety and efficacy of TROP2-directed antibody-drug conjugate (ADC) therapy in the management of advanced breast cancer; Identify common adverse events associated with the use of TROP2-directed agents in the management of advanced breast cancer; and Implement evidence-based best practices in the monitoring, identification and management of adverse events in patients with advanced breast cancer receiving TROP2-directed therapy.